Old Web
English
Sign In
Acemap
>
authorDetail
>
Sarah E. Dorff
Sarah E. Dorff
Food and Drug Administration
Internal medicine
Medicine
Immunology
Adverse effect
Isocitrate dehydrogenase
3
Papers
69
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
2020
Clinical Cancer Research
Elaine Chang
Chana Weinstock
Lijun Zhang
Rosane Charlab
Sarah E. Dorff
Yutao Gong
Vicky Hsu
Fang Li
Tiffany K. Ricks
Pengfei Song
Shenghui Tang
Peter E. Waldron
Jingyu Yu
Eias Zahalka
Kirsten B. Goldberg
Richard Pazdur
Marc R. Theoret
Amna Ibrahim
Julia A. Beaver
Show All
Source
Cite
Save
Citations (24)
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third Line Treatment of Metastatic Triple-negative Breast Cancer (mTNBC).
2020
Clinical Cancer Research
Sakar Wahby
Lola A. Fashoyin-Aje
Christy Osgood
Joyce Cheng
Mallorie H. Fiero
Lijun Zhang
Shenghui Tang
Salaheldin S. Hamed
Pengfei Song
Rosane Charlab
Sarah E. Dorff
Tiffany K. Ricks
Kimberly Barnett-Ringgold
Jeannette Dinin
Kirsten B. Goldberg
Marc R. Theoret
Richard Pazdur
Laleh Amiri-Kordestani
Julia A. Beaver
Show All
Source
Cite
Save
Citations (24)
Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis.
2020
Clinical Cancer Research
Kelly J. Norsworthy
Flora Mulkey
Emma C. Scott
Ashley F. Ward
Donna Przepiorka
Rosane Charlab
Sarah E. Dorff
Albert B. Deisseroth
Dickran Kazandjian
Rajeshwari Sridhara
Julia A. Beaver
Ann T. Farrell
R. Angelo de Claro
Richard Pazdur
Show All
Source
Cite
Save
Citations (21)
1